SEARCH

SEARCH BY CITATION

References

  • 1
    IARC. GLOBOCAN 2008, Section of Cancer Information. Available at: http://globocan.iarc.fr/factsheets/cancers/cervix.asp. Accessed on November 21, 2010.
  • 2
    Belinson JL, Qiao YL, Pretorius RG, Zhang WH, Elson P, Li L, Pan QJ, Fischer C, Lorincz A, Zahniser D. Shanxi Province Cervical Cancer Screening Study. A cross-sectional comparative trial of multiple techniques to detect cervical intraepithelial neoplasia. Gynecol Oncol 2001; 83: 43944.
  • 3
    Belinson JL, Qiao YL, Pretorius RG, Zhang WH, Rong SD, Huang MN, Zhao FH, Wu LY, Ren SD, Huang RD, Washington MF, Pan QJ, et al. Shanxi Province Cervical Cancer Screening Study II: self-sampling for high-risk human papillomavirus compared to direct sampling for HPV and liquid based cervical cytology. Int J Gyn Cancer 2003; 13: 18.
  • 4
    Belinson JL, Hu S, Niyazi M, Pretorius RG, Wang H, Wen C, Smith J, Li J, Taddeo F, Burchette R, Qiao YL. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal, and vaginal self-collected specimens; implications for vaginal self-collection. Int J Cancer 2010; 127: 11517.
  • 5
    Belinson JL, Wu RF, Belinson SE, Qu XF, Yang B, Du H, Wu RS, Wang C, Zhang LJ, Zhou YQ, Liu Y, Pretorius RG. A population based clinical trial comparing endocervical high-risk HPV testing using hybrid capture II and Cervista from the SHENCCAST II study. Am J Clin Pathol 2011; 135: 7905.
  • 6
    Wright TC, Jr, Denny L, Kuhn L, Pollack A, Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. J Am Med Assoc 2000; 283: 816.
  • 7
    Salmerón J, Lazcano-Ponce E, Lorincz A, Hernández M, Hernández P, Leyva A, Uribe M, Manzanares H, Antunez A, Carmona E, Ronnett BM, Sherman ME, et al. Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico. Cancer Cause Control 2003; 14: 50512.
  • 8
    Qiao Y-L, Sellors JW, Eder PS, Bao Y-P, Lim JM, Zhao F-H, Weigl B, Zhang W-H, Peck RB, Li L, Chen F, Pan Q-J, et al. A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008; 9: 92936.
  • 9
    Szarewski A, Cadman L, Mallett S, Austin J, Londesborough P, Waller J, Wardle J, Altman DG, Cuzick J. Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting. J Med Screen 2007; 14: 3442.
  • 10
    Einstein MH, Martens MG, Garcia FA, Mitchell AL, Day SP, Olson MC. Clinical validation of the Cervista HPV HR and 16/18 genotyping tests for use in women with ASC-US cytology. Gynecol Oncol 2010; 118: 11622.
  • 11
    Söderlund-Strand A, Dillner J, Carlson J. High throughput genotyping of oncogenic human papilloma viruses with MALDI-TOF mass spectrometry. Clin Chem 2008; 54: 8692.
  • 12
    Clavel C, Masure M, Bory JP, Putaud I, Mangeonjean C, Lorenzato M, Gabriel R, Quereux C, Birembaut P. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: a preliminary study on 1518 women. Br J Cancer 1999; 80: 130611.
  • 13
    Day SP, Hudson A, Mast A, Sander T, Curtis M, Olson S, Chehak L, Quigley N, Ledford J, Yen-Lieberman B, Kohn D, Quigley DI, et al. Analytical performance of the investigational use only Cervista HPV HR test as determined by a multi-center study. J Clin Virol 2009; 45( Suppl 1): S6372.
  • 14
    Castle PE, Schiffman M, Wheeler CM, Solomon D. Evidence for frequent regression of cervical intraepithelial neoplasia-grade 2. Obstet Gynecol 2009; 113: 1825.
  • 15
    Syriänen KJ. Spontaneous evolution of intraepithelial lesions according to the grade and type of the implicated human papillomavirus (HPV). Eur J Obstet Gynecol Repro Biol 1996; 65: 4553.
  • 16
    Belinson JL, Pretorius RG, Enerson C, Garcia F, Perez Cruz E, Belinson S, Yeverino Garcia E, Brainard J. The Mexican Cervical Cancer Screening Trial (MECCS): self-sampling for the human papillomavirus with unaided visual inspection as a secondary screen. Int J Gyn Cancer 2009; 19: 2732.
  • 17
    Tisci SE, Shen YH, Fife D, Goycoolea JM, Ma CP, Qiao YL, Belinson JL. Patient acceptance of self-sampling for human papillomavirus in rural China. J Lower Genital Tract Dis 2003; 7: 10716.
  • 18
    Sankaranarayanan R, Esmy PO, Rajkumar R, Muwonge R, Swaminathan R, Shanthakumari S, Fayette J-M, Cherian J. Effect of visual screening on cervical cancer incidence and mortality in Tamil Nadu, India: a cluster-randomised trial. Lancet 2007; 370: 398406.
  • 19
    Franceschi S, Cuzick J, Herrero R, Dillner J, Wheeler C. EUROGIN 2008 roadmap on cervical cancer prevention. Int J Cancer 2009; 125: 224655.
  • 20
    Samarawardana P, Dehn DL, Singh M, Franquemont D, Thompson C, Gaido L, Torkko KC, Homer P, Burke S, Titmus MA, Nayi V, Shroyer KR. p16(INK4a) is superior to high-risk human papillomavirus testing in cervical cytology for the prediction of underlying high-grade dysplasia. Cancer Cytopathol 2010; 118: 14656.